Gil Leurquin-Sterk
Gil Leurquin-Sterk is an expert in Nuclear medicine at Erasmus Hospital (Belgium). Gil Leurquin-Sterk has authored 18 publications, the most recent in 2023. SLR score: 54 (community average: 125). How the SLR is computed.
LeadR Profile
Nuclear medicine
Subspecialties:
Main Topics
Publications and Clinical Studies
Profile data updated on
Organizations
Career arc: 2011 - 2023
Number : 18
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Late-line treatment with bevacizumab alone or in combination with chemotherapy in recurrent high-grade gliomas. PMID 36781461 — neurosurgery, drug therapy, therapeutics, neoplasms, glioma, disease-free survival, promoter regions, genetic, bevacizumab, progression-free survival, chemotherapy | Acta Neurochir (Wien) | 2023 | 0 |
| Recording of Ictal Epileptic Activity Using on-Scalp Magnetoencephalography. PMID 36480016 — magnetoencephalography, neurology | Ann Neurol | 2022 | 25 |
| Clinical experience with F-JK-PSMA-7 when using a digital PET/CT. PMID 35288807 — prostate, drug therapy, positron emission tomography computed tomography, therapeutics, chemotherapy | Eur J Hybrid Imaging | 2022 | 7 |
| Voxelwise Principal Component Analysis of Dynamic [S-Methyl-C]Methionine PET Data in Glioma Patients. PMID 34066294 — glioma, principal component analysis, neoplasms, methionine, work | Cancers (Basel) | 2021 | 11 |
| Effects of alcohol exposure on the glutamatergic system: a combined longitudinal F-FPEB and H-MRS study in rats. PMID 29790622 — tobacco use disorder, alcoholism, hippocampus, positron-emission tomography, receptor, metabotropic glutamate 5 | Addict Biol | 2018 | 18 |
LeadR Networks
Main global connection map